Replies to post #143930 on Biotech Values

[mcbio]

It's a superficial red flag for those who don't look. PFE isn't interested in BC that much, and it has a similar candidate in more advanced stage development for different types of cancer. PFE has narrowed their oncology focus significantly.

Fair enough. We'll see how it plays out. Either way, I know I will never personally consider Puma given the questions and the fact that they are all in on just this one drug. Just too many questions and too much risk for me at its valuation.

[p3analyze]

How does neratinib differentiates self from lapatinib and afatinib, or the pfizer irreversible pan-HER TKI? TIA